Use of DEFA1 as a prognostic biomarker for acute ischemic stroke

Abstract

This invention belongs to the field of biomarker technology, specifically relating to the application of DEFA1 as a prognostic biomarker for acute ischemic stroke. This invention discovers... DEFA1 The gene was significantly expressed between patients with acute ischemic stroke who experienced vascular events or death within one year of onset and those who did not. DEFA1 Gene expression levels were significantly higher in patients who experienced vascular events or death than in those who did not; there were also significant differences in expression between patients with acute ischemic stroke who experienced the event within 3 months of onset and those who did not experience severe disability or death. DEFA1 The expression level of the gene was significantly higher in patients who experienced severe disability or death than in those who did not. DEFA1 showed good predictive ability in predicting whether patients with ischemic stroke would experience adverse outcomes within 1 year and / or 3 months after onset.

Images